Literature DB >> 9491821

Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.

G D Anderson1, A B Awan, C A Adams, N R Temkin, H R Winn.   

Abstract

AIMS: The objectives of this study were to determine the effect of brain trauma on the multiple pathways of metabolism of valproate and to evaluate the use of the urinary 6beta-hydroxycortisol to cortisol ratio in predicting changes in hepatic metabolism induced by brain injury.
METHODS: Fourteen patients with severe head injuries received a 15 mg kg(-1) loading dose and a maintenance dose of valproate to maintain therapeutic plasma concentrations. A minimum of one steady state trough blood sample and one dosage interval urine were collected during days 3-6 and during days 7-14 post-injury. Total and unbound valproate plasma concentrations were determined by gas chromatography-flame ionization detection (GC-FID) with and without ultrafiltration. Urinary valproate metabolites were measured by gas chromatography/mass spectrometry (GC-MS) (n = 10). Urinary 6beta-hydroxycortisol and cortisol concentrations were determined by high performance liquid chromatography (h.p.l.c.) (n = 14). Total intrinsic clearance (CL[int]) for valproate and individual formation clearances (CL[f]) to its major metabolites were calculated. Data obtained during baseline (days 3-6) were averaged for each patient and were compared with averaged data obtained from days 7 to 14 using a paired t-test.
RESULTS: Statistically significant increases in the CL(int), CL(f) of VPA glucuronide, 2-ene-VPA, and 4-OH-VPA pathways and the 6beta-hydroxycortisol to cortisol ratio were found. The percent change in the 6beta-hydroxycortisol to cortisol ratio correlated significantly with the changes in the CL(int) of valproate.
CONCLUSIONS: Brain trauma results in induction of multiple pathways of valproate metabolism and increases in the 6beta-hydroxycortisol to cortisol ratio, suggesting a non-specific enzyme induction in response to head injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491821      PMCID: PMC1873360          DOI: 10.1046/j.1365-2125.1998.00652.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  The urinary 6 beta-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase.

Authors:  J P Desager; E Dumont; C Harvengt
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

2.  Effects of model traumatic injury on hepatic drug metabolism in the rat. IV. Glucuronidation.

Authors:  L K Griffeth; G M Rosen; E J Rauckman
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

3.  Effects of model traumatic injury on hepatic drug metabolism in the rat. V. Sulfation and acetylation.

Authors:  L K Griffeth; G M Rosen; E J Rauckman
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

4.  Phenytoin pharmacokinetics in critically ill trauma patients.

Authors:  B A Boucher; J H Rodman; G S Jaresko; S N Rasmussen; C B Watridge; T C Fabian
Journal:  Clin Pharmacol Ther       Date:  1988-12       Impact factor: 6.875

5.  Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs.

Authors:  I Roots; R Holbe; W Hövermann; S Nigam; G Heinemeyer; A G Hildebrandt
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

6.  Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia.

Authors:  G D Anderson; C Pak; K W Doane; K G Griffy; N R Temkin; A J Wilensky; H R Winn
Journal:  Ann Pharmacother       Date:  1997-03       Impact factor: 3.154

7.  6 beta-hydroxycortisol in random urine samples as an indicator of enzyme induction.

Authors:  P Saenger
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

8.  Effects of model traumatic injury on hepatic drug metabolism in the rat. II. In vivo metabolism of hexobarbital and zoxazolamine.

Authors:  L K Griffeth; G M Rosen; E J Rauckman
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

9.  Effects of model traumatic injury on hepatic drug metabolism in the rat. I. In vivo antipyrine metabolism.

Authors:  L K Griffeth; G M Rosen; C Tschanz; E J Rauckman
Journal:  Drug Metab Dispos       Date:  1983 Nov-Dec       Impact factor: 3.922

10.  Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.

Authors:  A W Rettenmeier; W P Gordon; K S Prickett; R H Levy; J S Lockard; K E Thummel; T A Baillie
Journal:  Drug Metab Dispos       Date:  1986 Jul-Aug       Impact factor: 3.922

View more
  5 in total

1.  Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.

Authors:  Gail D Anderson; Nancy R Temkin; Asaad B Awan; H Richard Winn; Richard H Winn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

Authors:  Aaron M Cook; Muhammad S Zafar; Sally Mathias; Alejandra M Stewart; Ana C Albuja; Meriem Bensalem-Owen; Siddharth Kapoor; Robert J Baumann
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

3.  Apparent autoinduction of valproate beta-oxidation in humans.

Authors:  D B McLaughlin; J A Andrews; W D Hooper; G R Cannell; M J Eadie; R G Dickinson
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

4.  Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.

Authors:  Gail D Anderson; Todd C Peterson; Cole Vonder Haar; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Michael R Hoane
Journal:  AAPS J       Date:  2015-06-12       Impact factor: 4.009

Review 5.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.